Ground-breaking data demonstrates tissue repair with Istesso’s novel investigational medicines
Istesso’s new class of developmental drugs, which inhibit mitochondrial complex...
17th July 2025
Istesso appoints Dr Mike Owen to Board of Directors
Istesso, the leading adaptive tissue-repair company, is pleased to announce...
4th June 2025
Taylor Swift Problems: Rethinking Innovation in Medicine
I’ve been thinking about Taylor Swift - not for the usual reasons, but in the context of medical innovation.
10th February 2025
Creativity in drug development
CEO Lisa Patel wants to invite patients to the table and put their everyday experiences of living with chronic diseases at the forefront of future drug development.
16th October 2023
An important conversation
CEO Lisa Patel wants to invite patients to the table and put their everyday experiences of living with chronic diseases at the forefront of future drug development.
17th August 2023
A new approach to tackling chronic disease
CEO Lisa Patel discusses our approach to tackling chronic disease....
17th August 2023
CEO Lisa Patel features on 15 minutes with the doctor
Our CEO Lisa Patel booked an ‘appointment’ with Dr Vinay...
21st June 2023
CEO Lisa Patel explores the perception of ‘easy diseases’
What does it mean for a disease to be ‘easy’, and how do we define when a disease is ‘solved’?
19th May 2023
Istesso announces FDA Fast Track and Orphan Drug designation for MBS2320
Istesso Limited, the programmed disease resolution company, today announces that...
5th December 2022